HLHan Sin Lee

Han Sin Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Han Sin Lee has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Bae Jun Oh

    Daegu‐Gyeongbuk Medical Innovation Foundation, Daegu, Korea

    1 shared publication
  • Chan Woo Cho

    Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

    1 shared publication
  • Curie Ahn

    Transplantation Center, Seoul National University Hospital, Seoul, Korea

    1 shared publication
  • Du Yeon Shin

    Transplantation Research Center, Samsung Biomedical Research Institute, Seoul, Korea

    1 shared publication
  • Geun‐Soo Kim

    Transplantation Research Center, Samsung Biomedical Research Institute, Seoul, Korea

    1 shared publication
  • Gyuri Kim

    Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

    1 shared publication

Latest Publications

  • Open Access

    Protective effect of a novel clinical-grade small molecule necrosis inhibitor against oxidative stress and inflammation during islet transplantation

    by Gyuri Kim, Han Sin Lee, Bae Jun Oh, Youngsang Kwon, Hyunjin Kim, Seungyeon Ha, Sang-Man Jin, Jae Hyeon Kim


  • Open Access

    Enhanced effect of human mesenchymal stem cells expressing human TNF‐αR‐Fc and HO‐1 gene on porcine islet xenotransplantation in humanized mice

    by Han‐Sin Lee, Sanghyun Song, Du Yeon Shin, Geun‐Soo Kim, Jong‐Hyun Lee, Chan Woo Cho, Kyo Won Lee, Hyojun Park, Curie Ahn, Jaeseok Yang, et al.

    Background: Porcine islet xenotransplantation is considered an attractive alternative treatment for type 1 diabetes mellitus. However, it is largely limited because of initial rejection due to Instant Blood‐Mediated Inflammatory Reaction (IBMIR), oxidative stress, and inflammatory responses. Recently, soluble tumor necrosis factor‐ɑ receptor type I (sTNF‐αR) and heme oxygenase (HO)‐1 genes (HO‐1/sTNF‐αR) have been shown to improve the viability and functionality of porcine islets after transplantation.Methods: In this study, genetically modified mesenchymal stem cells (MSCs) expressing the HO‐1/sTNF‐αR genes (HO‐1/sTNF‐αR‐MSC) were developed using an adenoviral system, and porcine islet viability and function were confirmed by in vitro tests such as GSIS, AO/PI, and the ADP/ATP ratio after coculturing with HO‐1/sTNF‐αR‐MSCs. Subsequently, isolated porcine islets were transplanted underneath the kidney capsule of diabetic humanized mice without MSCs, with MSCs or with HO‐1/sTNF‐αR‐MSCs.Results: According to the results, the HO‐1/sTNF‐αR‐MSC‐treated group exhibited improved survival of porcine islets and could reverse hyperglycemia more than porcine islets not treated with MSCs or islets cotransplanted with MSCs. Moreover, the HO‐1/sTNF‐αR‐MSC group maintained its morphological characteristics and the insulin secretion pattern of transplanted porcine islets similar to endogenous islets in immunocompetent humanized mice.Conclusions: Our results suggest that HO‐1/sTNF‐αR‐MSCs are efficient tools for porcine islet xenotransplantation, and this study may provide basic information for pre‐clinical animal models and future clinical trials of porcine islet xenotransplantation.